— Technology Description
Researchers in Prof. Mario Feldman’s laboratory have developed a patented, versatile, cost-effective platform for creating new multivalent vaccines for a variety of Gram-negative and Gram-positive bacteria. This technology, glycoengineered outer membrane vesicles (geOM…
— Background: Recombinant vesicular stomatitis virus (VSV) has successfully been used to create a vaccine for Ebola virus that is currently on the market. Previously, Professor Sean Whelan and colleagues have exploited the VSV platform to create similar vectors for both SARS and MERS.
Technology: The…
— Species: Human
Target: SARS-CoV-2 nucleocapsid protein
Applications:
Description: Two recombinant fully human monoclonal antibodies that recognize SARS-CoV-2 spike protein (data below).
Related Web Links: Ellebedy Profile; Ellebedy Lab
— Species: Mouse
Target: SARS-CoV-2 spike protein
Applications:
Description: Four murine monoclonal antibodies that recognize SARS-CoV-2 spike protein. Data below includes avaiable antibodies (mCoV.1.1C02; mCoV.1.2C08; mCoV.1.2D09; mCoV.1.2F05).
Related Web Links: Ellebedy Profile; Ellebedy Lab
…
— Species: Human
Target: SARS-CoV-2 spike protein
Applications:
Description: Ten recombinant fully human monoclonal antibodies that recognize SARS-CoV-2 spike protein (data below).
Related Web Links: Ellebedy Profile; Ellebedy Lab
Available Antibodies
mAb name
Ag
30.0000
10.0…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
